Aurealis Therapeutics
Kuopio
About Aurealis Therapeutics
They exist to develop curative solutions that achieve total and faster healing for non-healing wounds and other complex inflammatory diseases with their four-in-one biologic drug, AUP-16. Their goal is to create solid Phase 2 clinical efficacy data in diabetic foot ulcers and non-clinical proof-of-concept data in other inflammatory diseases by end of 2022, and to engage with strategic partners to ensure that this game changing technology benefits millions of patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $19.0M
- Last round: Series Unknown (Nov 2024)
- Website: aurealistherapeutics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/aurealis-therapeutics-122638 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.